Effect of therapeutic phlebotomy on blood oxygen in patients with chronic obstructive lung diseases
DOI:
https://doi.org/10.59736/IJP.24.03.1088Keywords:
Chronic Obstructive Pulmonary Disease, Hematocrit, Therapeutic Phlebotomy , Secondary PolycythemiaAbstract
Background: Secondary polycythemia could be found in chronic obstructive lung disease (COPD) with chronic hypoxemia and it may also raise the blood viscosity. This experiment evaluated acute alterations in oxygenation, hematocrit, arterial blood gas indicators and pulmonary artery systolic pressure, as well as documented the symptoms after therapeutic phlebotomy.
Methods: The study is a quasi-experimental, single-arm, pre-pretest post-test study that took place at the Pulmonology Unit of Ayub Teaching Hospital, Abbottabad between November 2025 and March 2026. Eighty-seven COPD patients, whose hematocrit exceeded 56 percent were sampled consecutively. About 200-450 mL blood was taken out depending on the hematocrit level, and clinical status. The values of SpO 2, arterial blood gas values, and chosen symptoms were measured pre-phlebotomy and around 24-48 hours post-phlebotomy. Data were compared by use of paired statistical test SPSS 21 was used to analyze the data.
Results: The mean age was 62.15 ± 4.08 years; 62 (71.3%) patients were male, 62 (71.3%) were smokers, and 56 (64.4%) had severe COPD. Mean SpO₂ increased from 73.63 ± 3.53% to 80.78 ± 2.26% (p<0.001). Hematocrit decreased from 60.05 ± 1.46% to 52.25 ± 0.99% (p<0.001), while PaO₂ increased from 51.11 ± 2.91 to 59.71 ± 2.24 mmHg (p<0.001). PaCO₂ decreased from 45.31 ± 2.08 to 40.31 ± 2.08 mmHg, while pH increased from 7.32 ± 0.02 to 7.39 ± 0.02 (both p<0.001). Pulmonary artery systolic pressure also decreased from 51.32 ± 9.23 to 44.54 ± 7.35 mmHg (p<0.001).
Conclusion: Short-term patients with COPD and secondary polycythemia showed positive changes with the application of therapeutic phlebotomy. Yet, this uncontrolled before-after study is not able to determine a causal effect of treatment. There is a need to have controlled studies under standardized oxygen conditions and with extended follow-ups.
References
GOLD. Global Strategy for Prevention, Diagnosis and Management of COPD: 2024 Report. Global Initiative for Chronic Obstructive Lung Disease; 2024. Doi: goldcopd.org/2024-gold-report/
Adeloye D, Song P, Zhu Y, Campbell H, Sheikh A, Rudan I, et al. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. Lancet Respir Med. 2022;10(5):447-58.
doi:10.1016/S2213-2600(21)00511-9.
Celli BR, Fabbri LM, Aaron SD, Agusti A, Brook R, Criner GJ, et al. An updated definition and severity classification of chronic obstructive pulmonary disease exacerbations: The Rome proposal. Am J Respir Crit Care Med. 2021;203(1):24-36. doi:10.1164/rccm.202008-3141PP.
Vogelmeier CF, Buhl R, Burghuber O, Criner G, Martinez FJ, et al. Goals of COPD treatment:Focus on symptoms and exacerbations.RespirMed.2020;166:105938. doi: 10.1016/j.rmed.2020.105938.
Stolz D, Mkorombindo T, Schumann DM, Agusti A, Ash SY, Bafadhel M, et al. Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission. Lancet. 2022;400(10356):921-72. doi:10.1016/S0140-6736(22)01273-9.
Soriano JB, Kendrick PJ, Paulson KR, Gupta V, Vos T, et al. Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir Med. 2020;8(6):585-96.doi:10.1016/S2213-2600(20)30105-3.
Salvi S, Kumar GA, Dhaliwal RS, Paulson K, Agrawal A, Koul PA, et al. The burden of chronic respiratory diseases and their heterogeneity across the states of India: the Global Burden of Disease Study 1990-2016. Lancet Glob Health. 2018;6(12): e1363-e1374.
doi:10.1016/S2214-109X (18)30409-1.
Adeloye D, Chua S, Lee C, Basquill C, Papana A, Theodoratou E, et al. Global and regional estimates of COPD prevalence: systematic review and meta-analysis.J GlobHealth.2015;5(2):020415. doi:10.7189/jogh.05.020415.
Criner GJ, Han MK. COPD care in the 21st century: a public health priority. Chest. 2022;161(5):1219-30.
doi: 10.1016/j.chest.2021.11.026.
Weatherald J, Humbert M. Pulmonary hypertension in chronic lung disease. Eur RespirRev.2021;30(159):200315. doi:10.1183/16000617.0315-2020.
McMullin MF, Harrison CN, Ali S, Cargo C, Chen F, Ewing J, et al. A guideline for the diagnosis and management of polycythaemiavera.BrJHaematol.2019;184(2):176-91. doi:10.1111/bjh.15648.
Fuqua J, Reece M, Sofka CM. Secondary polycythemia in chronic respiratory disease: a case report. Hematol Rep. 2021;13(2):8961. doi:10.4081/hr.2021.8961.
Chetty KG, Light RW, Stansbury DW. Exercise performance of polycythemia COPD patients. Chest. 1990;98(5):1073-77. doi:10.1378/chest.98.5.1073.
Peedin AR, Karp JK. How do I perform therapeutic phlebotomy? Transfusion. 2021;61(3):673-677. doi:10.1111/trf.16279.
Ahmad A, Arora S, Baqar S. Therapeutic phlebotomy revisited: a review. Saudi J Med.2023;8(4):152-158.
doi:10.36348/sjm. 2023.v08i04.004.
Romón S, et al. Adverse effects of therapeutic phlebotomies: prospective study of 587 procedures. Transfusion. 2024;64(7):1262-69. doi:10.1111/trf.17845.
Leiva-Juárez MM, et al. Chronic respiratory disease and oxygen transport. FrontMed.2021;8:682456. doi:10.3389/fmed.2021.682456.
Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med. 1980;93(3):391-8. doi:10.7326/0003-4819-93-3-391.
Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet. 1981;1(8222):681-6. doi:10.1016/S0140-6736(81)91989-X.
Duffy SP, Criner GJ. Chronic obstructive pulmonary disease: evaluation and management. Chest.2021;160(6):2103-15. doi: 10.1016/j.chest.2021.07.042.
Gupta V, et al. Therapeutic phlebotomy: clinical experience from a tertiary care centre. Glob J Transfus Med. 2024;9(2):126-9. doi:10.4103/gjt_23_24.
Dhiman N, et al. Therapeutic phlebotomy: a five-year experience. Indian J Hematol BloodTransfus.2025;41(1):1-11. doi:10.1007/s12288-024-01783-w.
Martinez FJ, et al. Chronic obstructive pulmonary disease. Nat Rev Dis Primers. 2023;9(1):19.
doi:10.1038/s41572-023-00431-2.
Miravitlles M, Ribera A. Understanding the impact of symptoms and exacerbations in COPD. Ther Adv Respir Dis. 2020; 14:1-13. doi:10.1177/1753466620973016
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Marya Sharif Mughal, Umair Sharif Mughal, Khoula Sharif Mughal, Iqra Shabbir , Ahtezaz Hussain, Muhammad Yasin
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Readers may “Share-copy and redistribute the material in any medium or format” and “Adapt-remix, transform, and build upon the material”. The readers must give appropriate credit to the source of the material and indicate if changes were made to the material. Readers may not use the material for commercial purpose. The readers may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
